EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial

Ying Cheng, Panpan Zhang, Ming Lu, Zhendong Chen, Lijie Song, Si Shi, Feng Ye, Xing Zhang, Baorui Liu, Dongmei Ji, Yanqiao Zhang, Weiguo Su und 4 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-024-03932-x ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Ying Cheng und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jilin Cancer Hospital, 1066 Jinhu Rd, High-Tech Zone, Changchun, China. jl.cheng@163.com. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Combining the programmed death-1 inhibitor toripalimab and the angio-immuno kinase inhibitor surufatinib showed preliminary antitumor activity in patients with advanced solid tumors in a phase I study. Here, we report the efficacy and safety of this combination regimen in treatment-naive advanced or metastatic non-small-cell lung cancer (NSCLC) patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or greater (PD-L1-positive) and patients with previously treated small-cell lung cancer (SCLC). METHODS: This open-label, single-arm phase II study included patients with treatment-naive advanced or metastatic PD-L1-positive NSCLC or previously treated SCLC in China. Patients received surufatinib (250 mg orally, once daily) plus toripalimab (240 mg intravenously, once every 3 weeks). Primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1. Secondary endpoints included duration of response (DoR), disease control rate, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Forty-three patients were treated (NSCLC cohort, n = 23; SCLC cohort, n = 20). ORRs (95% CIs) were 57.1% (34.0-78.2) in the NSCLC cohort and 15.8% (3.4-39.6) in the SCLC cohort. Median duration of response was not reached (NR) in both cohorts. Median PFS was 9.6 (5.5-NR) and 3.0 months (2.8-4.1), respectively, and median OS was 24.3 (10.8-NR) and 11.0 months (5.0-15.7), respectively. Grade ≥ 3 treatment-related adverse events were reported in 24 patients (55.8%) overall. CONCLUSION: Surufatinib plus toripalimab showed encouraging antitumor activity and a tolerable safety profile in patients with treatment-naive advanced or metastatic PD-L1-positive NSCLC and previously treated SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

Combination therapyImmune checkpoint inhibitorImmunotherapyLung cancerSurufatinibToripalimab

Substanzen

toripalimabB7-H1 AntigenAntibodies, Monoclonal, HumanizedCD274 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Jilin Cancer Hospital, 1066 Jinhu Rd, High-Tech Zone, Changchun, China. jl.cheng@163.com.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Early Drug Development Centre, Peking University Cancer Hospital & Institute, Beijing, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer…
  • Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, No.678 Furong Road, Economic and Technological Development Zone, Hefei, Anhui, China.
  • First Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No.1 East Jianshe Road, Erqi District, Zhengzhou, Henan, China.
  • Department of Pancreatic Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, No.270 Dong'an Road, Xuhui District, Shanghai, China.

Zitieren

APA

Cheng, Y., Zhang, P., Lu, M., Chen, Z., Song, L., Shi, S., Ye, F., Zhang, X., Liu, B., Ji, D., Zhang, Y., Su, W., Shi, M., Fan, S., Tan, P., & Zhong, C. (2025). Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03932-x

Vancouver

Cheng Y, Zhang P, Lu M, Chen Z, Song L, Shi S, et al. Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-024-03932-x

BibTeX
@article{Cheng2025,
  author = {Cheng, Ying and Zhang, Panpan and Lu, Ming and Chen, Zhendong and Song, Lijie and Shi, Si and Ye, Feng and Zhang, Xing and Liu, Baorui and Ji, Dongmei and Zhang, Yanqiao and Su, Weiguo and Shi, Michael and Fan, Songhua and Tan, Panfeng and Zhong, Chen},
  title = {Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-024-03932-x}
}
Kostenlos starten →